Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06499233 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease

StatusRecruiting
PhasePhase 4
Started2024-07-20
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 1, 2024 (before its estimated July 20, 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2024-09-27
Study Status v2
Re-verified, no change to tracked fields
2024-07-11
Study Status, Study Description, Outcome Measures v1
Primary endpoints1 entry, revised
Number of participants with PJP infection
2024-07-06
Original filing
Tongji Hospital
197 trials monitored
See 2 trials at risk
This is an open-labeled, prospective clinical study aims at collecting and analyzing baseline characteristics of autoimmune inflammatory rheumatic disease (AIIRD) patients receiving sulfanilamide for preventive purposes, as well as subsequent follow-up data, in order to assess the efficacy and safety of the medication. Additionally, through a stratified analysis of risk factors, the investigators aim to identify the AIIRD population that would benefit most from preventive medication based on a favorable benefit-risk ratio.
Trial Details
NCT Number NCT06499233
Lead Sponsor Tongji Hospital
Conditions Pneumonia, Pneumocystis, Autoimmune Inflammatory Rheumatic Disease, Autoimmune Diseases, Connective Tissue Disease, Prevention
Enrollment 800 participants
Start Date 2024-07-20
Primary Completion 2026-07-20 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-01